Media Center

Events

2020
  • March - BIO-Europe Spring. Paris (France)
  • February - 15th Biomarkers Series UK. Manchester (United Kingdom) - Marc Yeste, PhD: Pharmacodynamic biomarkers associated to ABTL0812, a phase 2 clinical stage pro-autophagy anticancer drug
  • January - J. P. Morgan (USA)
2019
  • November - BIO-Europe. Hamburg (Germany)
  • September - ESMO: European Society for Medical Oncology. Barcelona
  • June - BIO International. Philadelphia (USA)
  • June - ASCO Annual Meeting. Chicago (USA)
  • May - MIXiii-Biomed 2019. Tel Aviv (Israel)
  • January - Invest Securities BioMed Event
  • January - 2019 Cholangiocarcinoma Foundation Annual Conference. Salt Lake City (USA)
2018
  • October - Pau Muñoz will defend the Doctoral thesis: "Mechanism of action of the new antitumour drug ABTL0812: Role of pseudoquinase TRIB3, reticular stress and sphingolipids in death mediated by autophagy". UAB (Bellaterra, Barcelona)
  • October - Sachs Forum. Basel (Switzerland)
  • September - BioSpain. Sevilla (Spain)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • June - II Biennal Congress of the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Rome (Italy)
  • May - Bio€quity Europe. Ghent (Belgum)
2017
  • November - BioEurope. Berlin (Germany)
  • October - CPhI Worldwide. Frankfurt (Germany)
  • September - ASEBIO Investors Day. Barcelona (Catalnoia)
  • September - Sachs Forum. Basel (Switzerland)
  • June - 2017 BIO International Convention. San Diego, CA (USA)
  • June - ASCO Annual Meeting. Chicago, IL (USA)
  • March - BioEurope. Barcelona (Catalonia - Spain)
  • March - 10th Annual European Life Sciences CEO Forum & Exhibition. Zurich (Switzerland)
2016
  • October - BioEurope. Cologne (Germany)
  • October - CPhI. Barcelona (Catalonia, Spain)
  • June - BIO international convention. San Francisco, CA (USA)
  • September - BioSpain. Bilbao (Spain)
  • September - BioJapan (Japan)
2015
  • November - AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Boston, MA (USA)
  • September - ESMO: European Society for Medical Oncology. Vienna (Austria)
  • May - IATI Biomed. Tel Aviv (Israel)
  • May - Biotrinity. London (UK)
  • April - Anglonordic Life Science Conference. (Spain)
  • February - BIO CEO & Investor Conference. New York, NY (USA)
2013
  • April - BIO International Convention. Chicago, IL (USA)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)
  • March - Company presentation at 6th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
  • January - Company presentation at Biotech Showcase at JP Morgan Healthcare Conference. San Francisco, CA (USA)
2012
  • September - Poster session at the 8th International Translational Oncology Symposium. Barcelona
  • July - Poster session at the meeting of the European Association for Cancer Research (EACR). Barcelona (Catalonia, Spain)
  • June - Booth at BIO International Convention. Boston, MA (USA)
  • June - Company presentation at the International Cancer Cluster Showcase. Boston, MA (USA)
  • April - Poster session at the meeting of the American Association for Cancer Research (AACR). Chicago, IL (USA)
  • March - Company presentation at 5th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2011
  • November - Company presentation at NYC Landmark Venture Forum - Investing for Cures. New York, NY (USA)
  • November - Company presentation at Foro Neotec (CDTI). Logrono (Spain)
  • September - Company presentation at MassBio’s Global Gateway. Boston, MA (USA)
  • September - Company presentation at BioPharm America. Boston, MA (USA)
  • May - Company presentation at Oncology Forum Farmaindustria. Madrid (Spain)
  • June - BIO International Convention. Washington, DC (USA)
  • May - 7th International Translational Oncology Symposium. Barcelona (Catalonia, Spain)
  • April - BioTrinity. Newbury (United Kingdom)
  • January - Company presentation at 4th Annual European Life Science CEO Forum for Partnering & Investing. Zurich (Switzerland)
2010
  • November - BioEurope. Munich (Germany)
  • November - Company presentation at European Venture Capital Contest Summit. Düsseldorf (Germany)
  • October - Company presentation at European Venture Capital Contest Semi-Final. Pamplona (Spain)
  • September - Company presentation at BioSpain. Pamplona (Spain)
  • August - Company presentation at European Venture Capital Contest Semi-Final. Aarhus (Denmark)
  • June - HiT Barcelona World Innovation Summit. Barcelona (Catalonia, Spain)
  • March - BioEurope Spring. Barcelona (Catalonia, Spain)

LATEST NEWS

05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

Press Release

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

Press Release

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

Press Release

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG